CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: However, a significant reduction in proportions of c-KIThi CML LT-HSCs and increase in proportions of c-KITlo CML LT-HSCs were seen following culture of CML CD34+ cells with nilotinib for 7 days (Figure 8, C and D).